Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27783825 | 0.82 | CYP3A4 (0.46) | ALDH1A1TSHRCA1CA2CA9 | |
| SCHEMBL23174468 | 0.82 | GAA (0.46) | CA1CA2CA3CA9GAA | |
| SCHEMBL29514060 | 0.77 | GAA (0.39) | ALDH1A1TSHRCYP3A4GAAMAPT | |
| SCHEMBL25346434 | 0.77 | GAA (0.39) | ALDH1A1TSHRCYP3A4GAAMAPT | |
| SCHEMBL18373638 | 0.75 | CA1 (0.33) | CA1CA2CA3CA9 | |
| SCHEMBL18101290 | 0.73 | TTR (0.33) | — | |
| SCHEMBL5080236 | 0.73 | HDAC1 (0.42) | ALDH1A1TSHRCA1CA2CA3 | |
| SCHEMBL8395028 | 0.73 | CYP3A4 (0.42) | ALDH1A1TSHRCYP3A4TP53GAA | |
| SCHEMBL111459 | 0.73 | CES2 (0.41) | ALDH1A1TSHRCA1CA2CYP3A4 | |
| SCHEMBL2929573 | 0.73 | CES2 (0.36) | ALDH1A1CA1CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707773-A | Preparation method and application of maleimide structure-containing compound | 中国农业大学 | 2025-03-28 | — | — | CN | claimed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| WO-2025133915-A1 | COMPOUNDS WHICH BIND TO PNPLA3I148M AND THEIR USE TO TREAT LIVER DISEASES | NOVARTIS AG (CH) | 2025-06-26 | — | — | WO | disclosed |
| CN-119707773-A | Preparation method and application of maleimide structure-containing compound | 中国农业大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-116507695-B | Aromatic isothiocyanates | 默克专利股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-117660019-A | Liquid crystal compound with high birefringence, synthesis method, liquid crystal composition and application | 西安近代化学研究所 | 2024-03-08 | — | — | CN | disclosed |
| CN-117534600-A | Isothiocyano trans-cyclohexyl biphenyl liquid crystal compound, and preparation method and application thereof | 武汉轻工大学 | 2024-02-09 | — | — | CN | disclosed |
| CN-117510315-A | dl- (±) -beta-methyl amyl terphenyl liquid crystal compound, preparation method and application thereof | 武汉轻工大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-117466897-A | Highly selective FGFR2 inhibitors | 深圳福沃药业有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117203307-A | Liquid-crystalline medium | 默克专利股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| CN-101580716-B | Terminal isothiocyano liquid-crystal compound containing pyrimidine ring and preparation method thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO LTD | 2013-04-17 | — | — | CN | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011098398-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098398-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| US-7767857-B1 | Preparation of 2,4,6,-trichloroaniline from aniline using N-chloro reagents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | ALDH1A1 2027/4885TSHR 846/4885CA1 3387/4885 |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | MDM2, TP53, TP53BP1 | ALDH1A1 2956/4885TSHR 2392/4885CA1 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.